Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VoxCell BioInnovation

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Roche Basel Switzerland

AbbVie and Roche hoping for speedy venetoclax approval

Leukaemia treatment could reach US and EU markets within months

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

- PMLiVE

Nestle continues pharma drive with Seres collaboration

Food giant to investigate potential inflammatory bowel disease treatments

- PMLiVE

The Maverick: giving medicines away free

Co-op biotech founder Andrew Hessel on how he wants to change the way medicines are discovered and paid for

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

Biogen’s Douglas Williams departs for biotech start-up

Research head will be first member of a new cancer-focused firm

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links